RO-948

Phase 1Small molecule

WWashington University School of Medicine

RO-948 is one of 36 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseRecruiting

Alzheimer's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

54 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

6 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Namenda

AbbVie

Phase 2

2 6

Briviact

UCB

Phase 2

1 7

Leukine

Sanofi

Phase 2

1 8

Niacor

AbbVie

Phase 2

1 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 10

Hytrin

AAbbott

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Study completion

NCT05464368

Clinical

Trials by Indication[1]

Unspecified1 trial

R21 Roche: 3-Way Tau Tracers in AD

Recruiting·WWashington University School of Medicine·Phase 1·NCT05464368·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO-948. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO-948 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO-948. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

RO-948

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News